ROS-triggerable dual nanocoated probiotics for inflammatory bowel disease treatment
Inflammatory bowel disease (IBD), an immune-mediated chronic gastrointestinal disease, is difficult to treat because its specific pathogenic mechanisms are currently unclear, and its recurrence rate is high. Probiotic therapies have been used to treat IBD; however, challenges, including poor digesti...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Taylor & Francis Group
2026-12-01
|
| Ráidu: | Drug Delivery |
| Fáttát: | |
| Liŋkkat: | https://www.tandfonline.com/doi/10.1080/10717544.2026.2630460 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|